Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hepatitis C virus subtype 1b

ABSTRACT: Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing

PROVIDER: PRJDB1886 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DRR000901_1.fastq.gz	Fastqsanger.gz
	DRR000901_2.fastq.gz	Fastqsanger.gz
	DRR000902_1.fastq.gz	Fastqsanger.gz
	DRR000902_2.fastq.gz	Fastqsanger.gz
	DRR000903_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 86

Similar Datasets

Hepatitis C virus subtype 1b

Project description:Hepatitis C virus subtype 1b Targeted Locus (Loci)

| PRJNA275480 | ENA

E-GEOD-48445

Project description:Gene expression profiling of liver biopsies from 21 chronic hepatitis C patients undergoing antiviral therapy

2025-01-24 | E-GEOD-48445 | ExpressionAtlas

Sandip2013 - Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.

Project description:Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin. Banerjee S1, Keval R, Gakkhar S. Author information 1 Department of Mathematics, Indian Institute of Technology Roorkee (IITR), Roorkee 247667, Uttaranchal, India. Electronic address: sandofma@iitr.ernet.in. Abstract A mathematical modeling of hepatitis C virus (HCV) dynamics and antiviral therapy has been presented in this paper. The proposed model, which involves four coupled ordinary differential equations, describes the interaction of target cells (hepatocytes), infected cells, infectious virions and non-infectious virions. The model takes into consideration the addition of ribavirin to interferon therapy and explains the dynamics regarding a biphasic and triphasic decline of viral load in the model. A critical drug efficacy parameter has been defined and it is shown that for an efficacy above this critical value, HCV is eradicated whereas for efficacy lower this critical value, a new steady state for infectious virions is reached, which is lower than the previous steady state value. Copyright © 2013 Elsevier Inc. All rights reserved. KEYWORDS: Hepatitis C virus (HCV); Infected cells; Infectious virions; Interferon; Noninfectious virions; Ribavirin; Target cells

2020-01-09 | MODEL1912120002 | BioModels

Sandip2013 - Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.

2024-09-02 | BIOMD0000000892 | BioModels

Hepatitis C virus subtype 1b

Project description:HCV NS5A sequencing

| PRJDB2979 | ENA

Hepatitis B virus

Project description:Ultra-deep sequencing of hepatitis B virus quasispecies in association with clinical status and nucleos(t)ide analogue treatment

| PRJDB2174 | ENA

Association Between Hepatitis C Infection and Renal Cell Carcinoma

Project description:The purpose of this study is to determine if there is an association between hepatitis C infection and kidney cancer. All patients who are diagnosed with kidney cancer and who will either have a biopsy or surgery will be offered to be tested for hepatitis C. The control group will be colon cancer patients. Both groups would be of recent diagnosis (6 months).

| 2110600 | ecrin-mdr-crc

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

Project description:The aim of this deep sequencing project is to determine whether treatment of chronically Hepatitis C infected chimpanzees with an antiviral compound leads to accumulation of viral mutants. The liver-expressed microRNA-122 (miR-122) is essential for hepatitis C virus (HCV) RNA accumulation in cultured liver cells, but its potential as a target for antiviral intervention has not been assessed. Here, we show that treatment of chronically infected chimpanzees with a locked nucleic acid (LNA)-modified oligonucleotide (SPC3649) complementary to miR-122 leads to long-lasting suppression of HCV viremia with no evidence for viral resistance or side effects in the treated animals. Furthermore, transcriptome and histological analyses of liver biopsies demonstrated derepression of target mRNAs with miR-122 seed sites, down-regulation of interferon-regulated genes (IRGs) and improvement of HCV-induced liver pathology. The prolonged virological response to SPC3649 treatment without HCV rebound holds promise of a new antiviral therapy with a high barrier to resistance.

2009-12-03 | GSE18919 | GEO

Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss

Project description:Hepatitis B virus (HBV) can integrate into the chromosomes of infected hepatocytes, contributing to the production of hepatitis B surface antigen (HBsAg) and to hepatocarcinogenesis. We performed spatial transcriptomics to investigate the intrahepatic cell heterogeneity and the spatial distribution of transcriptionally active HBV integration events in different phases of chronic HBV infection. Our analysis revealed that transcriptionally active HBV integration occurred in chronically HBV-infected patients in different phases, including those patients with HBsAg loss, and antiviral treatment was associated with a decreased number and extent of viral integrations.

2023-09-30 | GSE243367 | GEO

E-GEOD-66698

Project description:Liver gene expression profiles of interferon therapy in chronic hepatitis B Patients (mRNA)

2025-01-24 | E-GEOD-66698 | ExpressionAtlas